NCT00130286View on ClinicalTrials.gov

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
HIV-Associated Lipodystrophy SyndromeInsulin ResistanceHIV InfectionsMetabolic Syndrome XBody Weight Changes
Interventions
DRUG

Rosiglitazone

4 mg tablet twice a day x 12 weeks (double-blind phase)

DRUG

Recombinant human growth hormone + rosiglitazone

Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Trial Locations (4)

10018

AIDS Community Research Initiative of America (ACRIA), New York

10021

Cornell HIV Clinical Trials Unit, Weill Medical College of Cornell University, New York

10025

St. Luke's-Roosevelt Hospital Center, New York

10032

Columbia University College of Physicians and Surgeons, New York

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT00130286 - Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance | Biotech Hunter | Biotech Hunter